Analysts expect Autolus Therapeutics plc to report revenue of 40.29 M for Q2 26, against a range of 38.36 M to 42.22 M. The most recent reported quarter, Q1 26, came in at 26.22 M, a 2.1% beat against the 25.68 M consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 29,000.00 | 8.98 M | 20.92 M | 21.19 M | 24.29 M | 26.22 M | - | - | - | - |
| High Estimate | 98,205.64 | 151,555.47 | 3.28 M | 2.37 M | 14.82 M | 23.60 M | 24.98 M | 26.73 M | 42.22 M | 39.82 M | 42.52 M | 44.16 M |
| Low Estimate | 81,452.18 | 140,289.39 | 2.75 M | 1.97 M | 13.04 M | 21.41 M | 20.49 M | 24.63 M | 38.36 M | 33.36 M | 36.09 M | 37.71 M |
| Consensus Estimate | 89,828.91 | 145,922.43 | 3.01 M | 2.17 M | 13.93 M | 22.51 M | 22.74 M | 25.68 M | 40.29 M | 36.59 M | 39.31 M | 40.94 M |
Analysts expect Autolus Therapeutics plc to report earnings per share of -0.20 for Q2 26, against a range of -0.22 to -0.18. The most recent reported quarter, Q1 26, came in at -0.27, a 3.8% miss against the -0.26 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.22 | -0.31 | -0.09 | -0.26 | -0.18 | -0.30 | -0.34 | -0.27 | - | - | - | - |
| High Estimate | -0.17 | -0.19 | -0.18 | -0.21 | -0.19 | -0.19 | -0.26 | -0.25 | -0.18 | -0.18 | -0.16 | -0.16 |
| Low Estimate | -0.21 | -0.21 | -0.22 | -0.23 | -0.23 | -0.23 | -0.30 | -0.27 | -0.22 | -0.22 | -0.18 | -0.18 |
| Consensus Estimate | -0.19 | -0.20 | -0.20 | -0.22 | -0.21 | -0.21 | -0.28 | -0.26 | -0.20 | -0.20 | -0.17 | -0.17 |